- Home
- SRBK vs CNTB Comparison
SRBK vs CNTB Comparison
Compare SRBK & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$2.82
Company Overview
Basic Information| Metric | SRBK | CNTB |
|---|---|---|
| Founded | 1887 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.7M | 128.6M |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SRBK | CNTB |
|---|---|---|
| Price | $16.87 | $2.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 31.2K | ★ 116.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.19% | N/A |
| EPS Growth | ★ 138.36 | 75.22 |
| EPS | ★ 0.20 | N/A |
| Revenue | N/A | ★ $26,033,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $24,617.69 |
| P/E Ratio | $84.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.38 | $0.51 |
| 52 Week High | $18.04 | $3.28 |
Technical Indicators
Market Signals| Indicator | SRBK | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 50.26 | 56.38 |
| Support Level | $14.41 | $2.30 |
| Resistance Level | $17.14 | $2.86 |
| Average True Range (ATR) | 0.44 | 0.18 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 69.09 | 67.16 |
Price Performance
Historical Comparison SRBK
CNTB
About SRBK SR Bancorp Inc.
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.